Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0001193125-26-061712

Chief Executive Officer sold 6,967 shares at $52.58 ($366,325)

  • Chief Executive Officer acquired 13,250 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Kulkarni Samarth · Chief Executive Officer

Table I: Non-derivative

2 lines
Date Transaction Shares Price Value Owned after D/I
2026-02-18 Exercise or conversion : show line 1 in the form +13,250 233,073 D
2026-02-19 Sale : show line 2 in the form −6,967 $52.58 $366,325 226,106 D
Open-market sales · 6,967 sh · avg $52.58 · $366,325

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2026-02-18 Exercise or conversion : show line 3 in the form Restricted Stock Units −13,250 0 D
Loading xslF345X05/ownership.xml…